Vaginal Misoprostol Compared With Oral Misoprostol in Termination of Second‐Trimester Pregnancy

  title={Vaginal Misoprostol Compared With Oral Misoprostol in Termination of Second‐Trimester Pregnancy},
  author={Pak-chung Ho and Suk Wai Ngai and Ka Lai Liu and Grace Ching Yin Wong and Sharon W H Lee},
  journal={Obstetrics \& Gynecology},
Efficacy of Two Regimens of Misoprostol for Early Second-Trimester Pregnancy Termination
It is suggested that oral misoprostol combined with vaginal misopostol does not reduce the induction-to-abortion interval compared to an exclusively vaginal route when used for early 2nd-trimester pregnancy termination.
Comparative Study of Sublingual and Vaginal Misoprostol in Second Trimester Induced Abortion
Both sublingual and vaginal routes of misoprostol are equally effective in medical termination of pregnancy in second trimester but sublingUAL route was preferred by the women.
Vaginal Misoprostol Compared With Buccal Misoprostol for Termination of Second-Trimester Pregnancy: A Randomized Controlled Trial
Vaginal compared with buccal misoprostol administration has a shorter induction-to-abortion interval for second-trimester termination of viable pregnancies, however, both administration routes are equally effective for induction of termination.
Preference and acceptability of oral versus vaginal administration of misoprostol in medical abortion with mifepristone.
Comparison of oral versus vaginal misoprostol for mid-trimester pregnancy termination.
Main outcome measures of the study were induction-expulsion interval, need for surgical evacuation and maternal complications.
Frequent low-dose misoprostol for termination of second-trimester pregnancy
The 100-μg oral misoprostol every 2 h following 200 μg vaginal misop frostol is a highly effective protocol for inducing abortion at 12–20 weeks of pregnancy.
Vaginal misoprostol as medical treatment for first trimester spontaneous miscarriage.
BACKGROUND Misoprostol is effective for cervical priming prior to suction evacuation in first trimester pregnancy termination. This is the first randomized study to compare vaginal misoprostol versus
A randomized trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion at 13-20 weeks gestation.
Sublingual administration of misoprostol following mifepristone is an acceptable and effective alternative to vaginal administration for medical abortion at 13-20 weeks gestation, however, women should be advised about the greater likelihood of requiring stronger analgesia.


A comparison of intravaginal misoprostol with prostaglandin E2 for termination of second-trimester pregnancy.
Misoprostol is at least as effective as PGE2 for the termination of second-trimester pregnancy involving either a dead or a living fetus, but it is less costly, is easier to administer, and is associated with fewer adverse effects.
The abortifacient effect of misoprostol in the second trimester. A randomized comparison with gemeprost in patients pre-treated with mifepristone (RU486).
It is concluded that misoprostol is a stable, cheap PGE1 analogue with demonstrable efficacy and acceptable side-effects in the management of second trimester abortion.
Induction of abortion in the second trimester by a combination of misoprostol and mifepristone: a randomized comparison between two misoprostol regimens.
It is recommended that, following pre-treatment with mifepristone, misoprostol is used as the prostaglandin of choice to induce abortion in the second trimester.
Methotrexate and misoprostol vs misoprostol alone for early abortion. A randomized controlled trial.
Methotrexate and vaginal misoprostol are more effective than misop frostol alone and may offer an alternative to the use of antiprogestin and prostaglandin for medical abortion.
The use of mifepristone prior to prostaglandin-induced mid-trimester abortion.
There was a significant reduction in the induction to abortion interval, dose of prostaglandin required and attendant side effects in all three treated groups compared to controls, and it is suggested that mifepristone could be administered safely prior to hospital admission for termination.
Reducing the induction to abortion interval in termination of second trimester pregnancies: a comparison of mifepristone with laminaria tent
Whether mifepristone (RU486) is more effective than laminaria tent in shortening the induction‐abortion interval in termination of second trimester pregnancies with gemeprost is investigated.